FATS蛋白在非小细胞肺癌中的表达及其与预后的关系
该研究采用免疫组化和Western blot检测140例NSCLC及30例癌旁正常组织中FATS蛋白表达,分析其与临床病理特征和预后的关系。结果显示NSCLC中FATS高表达率40.0%,低于癌旁组织73.3%(P=0.01);FATS高表达组6年OS和DFS均显著优于低表达组,FATS表达是OS和DFS的独立影响因素。
要点
- NSCLC组织FATS高表达率40.0%,低于癌旁组织73.3%(P=0.01)。
- FATS表达与TNM分期(P=0.044)和N分期(P=0.022)相关。
- FATS高表达组6年OS和DFS显著优于低表达组(均P=0.001)。
核心结论
- FATS蛋白表达与NSCLC发生发展相关,是NSCLC患者预后的独立影响因素。
- FATS检测有望成为判断NSCLC预后的新生物标志物。
研究设计与样本
- 采用免疫组化和Western blot检测140例NSCLC组织和30例癌旁正常组织的FATS蛋白表达水平。
- 分析FATS蛋白表达与临床病理特征及预后的关系,并进行Cox多因素分析。
主要发现
- Western blot显示癌旁正常组织FATS表达显著高于NSCLC组织。
- 免疫组化显示140例NSCLC FATS高表达率40.0%,30例癌旁组织73.3%,差异有统计学意义(P=0.01)。
- FATS高表达组与低表达组间TNM分期(P=0.044)和淋巴结转移(P=0.022)差异有统计学意义。
- FATS高表达组和低表达组6年OS率分别为57.1%和23.8%,6年DFS率分别为53.6%和21.4%,差异均有统计学意义(均P=0.001)。
- Cox多因素分析显示性别、TNM分期和FATS表达是OS和DFS的独立影响因素。
关键数值与推荐
- FATS高表达组6年OS率为57.1%,低表达组为23.8%(P=0.001)。
- FATS高表达组6年DFS率为53.6%,低表达组为21.4%(P=0.001)。
- Cox多因素分析中FATS表达对OS的HR=0.532(P=0.010),对DFS的HR=0.538(P=0.009)。
- Cox多因素分析中性别对OS的HR=1.658(P=0.028),对DFS的HR=1.684(P=0.023)。
- Cox多因素分析中TNM分期对OS的HR=2.327(P=0.019),对DFS的HR=2.332(P=0.013)。
临床怎么用
- FATS蛋白检测可作为NSCLC患者预后评估的潜在生物标志物。
- FATS低表达提示预后较差,可能需更密切的随访或辅助治疗决策参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the expression of fragile-site associated tumor suppressor (FATS) in non-small cell lung cancer and its relationship with clinicopathological features and prognosis. Methods: A total of 140 non-small cell lung cancer (NSCLC) cases and 30 adjacent normal tissues were used to detect the expression level of FATS protein, and to analyze the relationship of FATS protein expression and clinicopathological features and prognosis of NSCLC. Results: Western blot showed that the expression of FATS in adjacent normal tissues was significantly higher than that in non-small cell lung cancer tissues. The results of immunohistochemistry showed that the high expression rate of FATS in 140 cases of NSCLC was 40.0%, and the high expression rate of FATS in 30 cases of adjacent tissues was 73.3%. The difference was statistically significant (P=0.01). Further analysis showed that the TNM stage (P=0.044) and lymph node metastasis (P=0.022) were significant difference between FATS high expression group and low expression group. The 6-year overall survival (OS) rates of NSCLC patients with FATS high-expression and low-expression were 57.1% and 23.8%, respectively, and the 6-year disease-free survival (DFS) rates were 53.6% and 21.4%, respectively, with statistically significant differences (P=0.001). In Cox multivariate analysis, we found gender (HR=1.658, P=0.028; HR=1.684, P=0.023), TNM staging (HR=2.327, P=0.019; HR=2.332, P=0.013) and FATS expression (HR=0.532, P=0.010; HR=0.538, P=0.009) were independent prognostic factors for both OS and DFS of NSCLC patients. Conclusions: The expression of FATS protein is associated with the development and is an independent prognostic factor of NSCLC patients. The detection of FATS protein is expected to be a new biomarker for evaluating the prognosis of NSCLC patients. 目的: 探讨脆性位点相关的肿瘤抑制因子(fragile-site associated tumor suppressor,FATS)在非小细胞肺癌(NSCLC)组织中的蛋白表达及其与临床病理特征和预后的关系。 方法: 采用免疫组化和Western blot方法检测140例NSCLC和30例癌旁正常组织的FATS蛋白表达水平,分析FATS的蛋白表达与临床病理特征和预后的关系。 结果: Western blot检测结果显示,NSCLC组织中FATS蛋白的表达低于癌旁组织。免疫组化检测结果显示,140例NSCLC组织FATS高表达率为40.0%,30例癌旁组织FATS高表达率为73.3%,差异有统计学意义(P=0.01)。NSCLC组织中FATS的表达与TNM分期(P=0.044)、N分期有关(P=0.022)。FATS高表达组和低表达组NSCLC患者的6年总生存率分别为57.1%和23.8%,6年无病生存率分别为53.6%和21.4%,差异均有统计学意义(均P=0.001)。Cox多因素分析显示,性别(HR=1.658,P=0.028;HR=1.684,P=0.023)、TNM分期(HR=2.327, P=0.019;HR=2.332,P=0.013)和FATS表达(HR=0.532,P=0.010;HR=0.538,P=0.009)是NSCLC患者总生存和无病生存的独立影响因素。 结论: FATS表达与NSCLC的发生发展相关,是NSCLC患者预后的独立影响因素,FATS有望成为判断NSCLC预后的新的生物标志物。.
引用
- Zhang TM, Zhang J, Zhou DJ, et al. [Expression of FATS in non-small cell lung cancer and its relationship with prognosis]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31770849. doi:10.3760/cma.j.issn.0253-3766.2019.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。